InvestorsHub Logo
Followers 283
Posts 31200
Boards Moderated 0
Alias Born 07/06/2012

Re: None

Tuesday, 12/31/2013 12:31:24 PM

Tuesday, December 31, 2013 12:31:24 PM

Post# of 410434
ELTP YTD ~~~ +58.8% ~~~not too shabby LONGS!

Have a Happy & Safe New Years everyone! I certainly got what I wanted this year and am feeling thankful for Nasrat Hakim becoming CEO!

Nasrat Hakim ~~~ THE CLOSER $$$$$$$$$

Elite has met the goal of starting the bio study for ELI-201 in December. A pivotal bioequivalence study for a second abuse deterrent product is scheduled to begin dosing in January 2014, and the pivotal bioequivalence study for ELI-201 is scheduled to begin dosing in March 2014. The bioequivalence studies for these opioid abuse deterrent products are being conducted under the direction of Camargo Pharmaceutical Services.

“The start of the ELI-201 pilot study marks a major milestone for the development of products utilizing our proprietary abuse deterrent technology,” said Nasrat Hakim, Elite’s President and CEO. “I am extremely pleased with the progress Elite has made with the development of this technology. We have set several initiatives in motion and all of our research and development projects are on or ahead of schedule. We appreciate the guidance and expertise that has been provided by Camargo and look forward to this next phase for the Company.”


Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News